Status:
COMPLETED
HIV And Parasitic Infection (HAPI) Study
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Fogarty International Center of the National Institute of Health
Conditions:
HIV Coinfection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The overall goal of this study is to determine if periodic de-worming of persons living with HIV in intestinal parasite-endemic regions will lead to decreased morbidity and mortality associated with H...
Detailed Description
This is a prospective study in which participants will be enrolled in outpatient HIV clinics associated with Kamuzu Central Hospital in Lilongwe, Malawi, where there are over 25,000 patients in care w...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- currently living in Malawi
- HIV-1 infection
- on ART ≥ 1 year with undetectable HIV RNA level at the last evaluation
- willingness to be treated with anti-parasitic therapy if infection with intestinal parasite is identified.
Exclusion
- Use of antibiotics other than prophylaxis with trimethoprim-sulfamethoxazole within 60 days of screening
- Use of antiparasitic medication (ex- albendazole, praziquantel, metronidazole) in the last year
- Inflammatory bowel disease
- Gastrointestinal tract malignancy
- Major intestinal surgery during prior 2 years
- Coinfection with Mycobacterium tuberculosis
- Pregnancy, breastfeeding mother, or planning pregnancy.
Key Trial Info
Start Date :
May 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05323396
Start Date
May 2 2022
End Date
August 4 2023
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lighthouse Clinic
Lilongwe, Malawi